Written by Aisha Saleem, Pharmacist & Health Writer at PharmaHealths.com
Last Updated: August 2026
Stopping antidepressants is one of the most common things people search for after starting them, and one of the most poorly served topics in patient facing content. The usual advice to reduce slowly over a few weeks with your doctor is correct, but often not enough for many people. Most people who struggle to come off antidepressants are not doing something wrong. They are often using a tapering approach that does not match the pharmacology of the drug. This article covers what the clinical research actually supports, how to distinguish withdrawal from relapse, and why the conventional tapering schedule often fails at exactly the point people need it most.
Key Takeaways
• Do not stop antidepressants suddenly
• Withdrawal symptoms can look like relapse, but timing helps tell the difference
• Most people need months, not weeks, to taper comfortably
• Lower doses require slower reductions
• Some drugs are harder to stop due to shorter half-life
When Is the Right Time to Consider Stopping?
NICE Guideline NG222 on Depression in Adults recommends that antidepressants should be continued for at least 6 to 12 months following remission of a depressive episode to reduce the risk of relapse. For people who have had three or more depressive episodes, or where episodes have been severe or difficult to treat, longer-term maintenance treatment is typically recommended and stopping may carry more risk than continuing.
Before planning to taper, the relevant clinical questions are:
• Have you been in remission for at least 6 months?
• Are you in a stable period of life with the capacity to notice and respond to returning symptoms?
• Have you discussed your individual relapse risk with your prescriber based on your specific history?
These are not barriers to stopping, they are the groundwork for stopping safely.
According to the National Institute of Mental Health, depression is a highly recurrent condition, with the risk of further episodes increasing after each one experienced. This is the clinical context in which any tapering decision should be made.
Why Abrupt Stopping Is Clinically Problematic
Stopping antidepressants suddenly without a planned taper produces a predictable set of physical and psychological symptoms in a significant proportion of people. This is not addiction. Antidepressants do not cause addiction or dependence in the clinical sense. What they produce is neuroadaptation: the brain adjusts to the presence of the drug over time, and a sudden absence disrupts that equilibrium.
A systematic review of SSRI discontinuation symptoms published in Psychotherapy and Psychosomatics by Fava and colleagues found that withdrawal symptoms occur in a substantial proportion of people stopping SSRIs, range from mild to severe in intensity, and are poorly recognized and documented in clinical practice. Critically, the review found that clinical guidelines at the time significantly underestimated both the incidence and the duration of these symptoms.
Antidepressant Discontinuation Syndrome: What It Feels Like
Discontinuation syndrome typically appears within 24 to 72 hours of a dose reduction or cessation and resolves within 2 to 4 weeks for most people. The most characteristic symptoms include:
Neurological: dizziness, balance disturbance, and brain zaps, brief electric shock sensations in the head or body that are one of the most distinctive and underreported features of SSRI discontinuation. If you experience brain zaps within a day or two of reducing your dose, that is discontinuation syndrome.
Flu like: fatigue, muscle aches, sweating, chills.
Gastrointestinal: nausea, diarrhea.
Sleep disturbance: vivid or disturbing dreams, insomnia, or excessive sleeping.
Mood and emotional: irritability, tearfulness, anxiety, low mood.
The presence of neurological symptoms, particularly brain zaps and dizziness, in the days immediately after a dose change is a strong clinical indicator of discontinuation syndrome rather than depression returning.
Withdrawal vs Relapse: The Most Important Distinction
Confusing withdrawal with relapse is one of the most consequential errors in antidepressant tapering. When mood symptoms appear after stopping, both the person and sometimes their clinician conclude that the depression is returning, when what is actually happening is a withdrawal reaction. This leads to people restarting medication unnecessarily, confirming a false belief that they cannot function without it.
A systematic review by Davies and Read published in Addictive Behaviors examined the severity and duration of antidepressant withdrawal effects across published research. The review found that a significant proportion of people experience withdrawal symptoms that are severe and extend well beyond the 1-to-2-week window described in most clinical guidelines, and identified that the overlap between withdrawal symptoms and depression symptoms makes reliable distinction genuinely difficult without attention to timing and symptom type.
The practical clinical distinction is this: withdrawal typically starts within a few days of the dose reduction, includes physical and neurological symptoms such as brain zaps, dizziness, and flu like sensations that are not typical features of depression, and tends to improve over time without further dose change. Relapse typically develops gradually over several weeks after stopping, resembles the original depressive presentation without the neurological features, and progressively worsens rather than improving.
If mood disturbance appears within 3 to 5 days of a dose reduction, discontinuation syndrome is the more likely explanation. If low mood and loss of interest gradually worsen starting 4 to 6 weeks after stopping, relapse is more likely.
Why Standard Tapering Schedules Often Fail: The Case for Hyperbolic Tapering
The most clinically significant advance in antidepressant tapering in recent years is the understanding that standard linear dose reductions, for example reducing by 25 mg every 2 weeks, are based on a fundamental misunderstanding of pharmacology.
A landmark paper by Horowitz and Taylor published in The Lancet Psychiatry in 2019 demonstrated that the relationship between antidepressant dose and serotonin transporter occupancy follows a hyperbolic curve, not a linear one. This means that reductions from higher doses have a much smaller proportional effect on the brain than reductions at lower doses, even when the milligram step is identical.
Cutting from 10 mg to 5 mg of an SSRI is proportionally a far larger neurobiological change than cutting from 50 mg to 25 mg, despite the milligram reduction being smaller. The practical implication is that tapering should be done in proportional steps, reducing by a percentage of the current dose each time, rather than equal milligram amounts throughout. For many people, the final steps of tapering at very low doses are the hardest, not the first steps at higher doses.
For example, instead of equal reductions, a hyperbolic taper may look like this: 20 mg to 15 mg to 12 mg to 9 mg to 7 mg to 5 mg to 3.5 mg to 2 mg to 1 mg before stopping.
This is why so many people successfully reduce from 100 mg to 25 mg without difficulty, then find the final steps near-impossible. Standard schedules that remove equal amounts all the way to zero consistently underestimate the neurobiological burden of the final phase. In simple terms, the biggest adjustment happens at the lowest doses, not the highest. Hyperbolic tapering specifically addresses this by slowing down precisely where most tapers fail.
Which Antidepressants Are Hardest to Stop
Half-life is the primary pharmacological factor determining how difficult a given antidepressant is to stop. Short half-life drugs leave the system quickly, producing a sharp and rapid drop in serotonin availability and more pronounced discontinuation symptoms. Long half-life drugs taper themselves more gradually.
Paroxetine is consistently the most difficult SSRI to discontinue. It’s very short half-life and anticholinergic properties combine to produce some of the most intense and prolonged discontinuation syndromes of any antidepressant.
Venlafaxine, an SNRI, is also notably difficult, particularly at lower doses.
Sertraline and escitalopram are intermediate in difficulty, easier than paroxetine and venlafaxine but still requiring a thoughtful and gradual taper.
Fluoxetine is the easiest antidepressant to stop due to its long half-life and active metabolite, which allow the drug to self-taper slowly after the last dose. Switching from a short half-life antidepressant to fluoxetine before discontinuing is a recognized clinical strategy for people who have struggled with standard tapers.
Practical Tapering: What This Looks Like
For most people, a gradual taper over several months, rather than several weeks, meaningfully reduces the risk of significant discontinuation symptoms. The pace should be individualized based on the specific drug, the dose, the duration of treatment, and how the person responds at each step.
A commonly used approach is reducing the dose by about 10 to 25 percent of the current dose every 2 to 4 weeks, adjusted based on symptoms.
A useful working principle: if a dose reduction produces tolerable symptoms that resolve within 1 to 2 weeks, the next reduction can proceed. If symptoms are significant or prolonged, staying at the current dose for longer before reducing again is clinically appropriate. There is no universal schedule.
Liquid formulations allow very precise dose reductions at low doses and are particularly useful during the final phase of a slow taper. For antidepressants available in liquid form, these are worth requesting specifically for the low dose phase. For antidepressants without manufacturer-produced liquid forms, compounded lower-dose preparations may be available through specialist or compounding pharmacies in some healthcare settings.
Protracted Withdrawal: When Symptoms Last Longer
A subset of people experiences withdrawal symptoms that persist for months rather than weeks. This is not well characterized in clinical literature and is widely underacknowledged in clinical practice. If symptoms that began after a dose reduction are still present after several months despite remaining at a stable dose, that warrants specialist review. Possible approaches include a very slow continued taper, temporary dose reinstatement followed by a much more gradual reduction, or specialist consultation with someone experienced in deprescribing. This is not a common outcome, but it is real, and acknowledging it matters.
Conclusion
Stopping antidepressants safely is more complex than most guides suggest, and most people who struggle are not failing, they are using a method that does not account for how these drugs actually work in the brain. Hyperbolic tapering, individualized to the person and the drug, is the approach that the clinical evidence increasingly supports. The ability to distinguish withdrawal from relapse, knowing which drugs are harder to stop and why, taking enough time, and not interpreting difficulty as evidence of permanent dependence are the four things that make the difference between a taper that works and one that feels impossible.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. Never stop, reduce, or change antidepressant medication without guidance from a qualified healthcare professional. If you are experiencing symptoms of depression or a mental health crisis, please contact your clinician or a mental health emergency service in your area.
References
• National Institute of Mental Health. Depression. https://www.nimh.nih.gov/health/topics/depression
• Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychotherapy and Psychosomatics. 2015;84(2):72-81. https://www.karger.com/Article/Abstract/370338
• Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addictive Behaviors. 2019;97:111-121. https://www.sciencedirect.com/science/article/pii/S0306460318308347
• Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. 2019;6(6):538-546. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30032-X/fulltext
• National Institute for Health and Care Excellence. Depression in Adults: Treatment and Management. NICE Guideline NG222. 2022. https://www.nice.org.uk/guidance/ng222
